"Over the last few years the company has developed a pipeline of product opportunities based on the CombiPlex technology," said Nicole Vitullo, partner at Domain Associates. "We believe that Celator's products may well represent the next generation of chemotherapeutics."
Kenneth Galbraith, general partner at Ventures West, joins Celator's Board of Directors. Mr. Galbraith is a well-known and active member of the North American life sciences community with over 20 years of experience acting as an executive, director, investor and advisor to companies in the biotechnology, medical device, pharmaceutical and healthcare sectors.
Celator Pharmaceuticals, Inc., with locations in Princeton, NJ, and
Vancouver, BC, is a privately held pharmaceutical company developing new
and more effective therapies to treat cancer. CombiPlex(TM), the company's
drug ratio technology platform, represents a revolutionary new approach to
the development of combination therapies based on identifying a fixed,
synergistic ratio of the drugs pre-clinically, incorporating that ratio in
a drug delivery vehicle and maintaining the ratio in patients. The company
pipeline includes: CPX-1 (a liposomal formulation of
irinotecan:floxuridine), currently in a Phase 2 trial in patients with
colorectal cancer; CPX-351 (a liposomal formulation of
cytarabine:daunorubicin), currently in a Phase 1 trial in patients with
leukemia; CPX 571 (a liposomal formulation of irinotecan:cisplatin), a
pre-clinical stage compound; and multiple research programs. Based on the
applications of CombiPlex, Celator is positioned to advance a broad
pipeline of combination therapies involving both previously approved and
novel drug agents. For more information, please visit the company's website
|SOURCE Celator Pharmaceuticals|
Copyright©2008 PR Newswire.
All rights reserved